Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway.

[1]  L. Videla,et al.  Up-regulation of PPAR-gamma mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction. , 2011, The Journal of clinical endocrinology and metabolism.

[2]  Jun Hee Lee,et al.  Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression , 2010, Cell.

[3]  N. Sata,et al.  Identification of transforming activity of free fatty acid receptor 2 by retroviral expression screening , 2010, Cancer science.

[4]  D. Sabatini,et al.  An Emerging Role of mTOR in Lipid Biosynthesis , 2009, Current Biology.

[5]  M. Vinciguerra,et al.  Unsaturated fatty acids promote hepatoma proliferation and progression through downregulation of the tumor suppressor PTEN. , 2009, Journal of hepatology.

[6]  M. Vinciguerra,et al.  Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA‐21 up‐regulation in hepatocytes , 2009, Hepatology.

[7]  Shankar Subramaniam,et al.  Diet‐induced hepatocellular carcinoma in genetically‐predisposed mice , 2009, Human molecular genetics.

[8]  A. Suzuki,et al.  Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice. , 2009, Journal of hepatology.

[9]  A. Krasnitz,et al.  An Oncogenomics-Based In Vivo RNAi Screen Identifies Tumor Suppressors in Liver Cancer , 2008, Cell.

[10]  Gary Hardiman,et al.  Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. , 2008, Cancer cell.

[11]  Y. Yamaji,et al.  The Effect of Body Weight Reduction on the Incidence of Colorectal Adenoma , 2008, The American Journal of Gastroenterology.

[12]  M. Vinciguerra,et al.  PTEN at the crossroad of metabolic diseases and cancer in the liver. , 2008, Annals of hepatology.

[13]  M. Loda,et al.  Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis , 2008, Nature.

[14]  A. Krasnitz,et al.  DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. , 2008, Genes & development.

[15]  Q. Zeng,et al.  The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. , 2008, Cancer cell.

[16]  Carmen Blanco-Aparicio,et al.  PTEN, more than the AKT pathway. , 2007, Carcinogenesis.

[17]  Marc-André Elsliger,et al.  Rare cancer-specific mutations in PIK3CA show gain of function , 2007, Proceedings of the National Academy of Sciences.

[18]  S. Yamaoka,et al.  Role of the Toll-like Receptor 4/NF-&kgr;B Pathway in Saturated Fatty Acid–Induced Inflammatory Changes in the Interaction Between Adipocytes and Macrophages , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[19]  W. Sellers,et al.  Mechanistic insights into maintenance of high p53 acetylation by PTEN. , 2006, Molecular cell.

[20]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[21]  Satoru Takahashi,et al.  Transgenic rescue of erythroid 5‐aminolevulinate synthase‐deficient mice results in the formation of ring sideroblasts and siderocytes , 2006, Genes to cells : devoted to molecular & cellular mechanisms.

[22]  Li Zhao,et al.  Oncogenic PI3K deregulates transcription and translation , 2005, Nature Reviews Cancer.

[23]  T. Kawabe,et al.  Functional analysis of PIK3CA gene mutations in human colorectal cancer. , 2005, Cancer research.

[24]  Carlo Rago,et al.  Mutant PIK3CA promotes cell growth and invasion of human cancer cells. , 2005, Cancer cell.

[25]  M. Malaguarnera,et al.  Heme oxygenase-1 levels and oxidative stress-related parameters in non-alcoholic fatty liver disease patients. , 2005, Journal of hepatology.

[26]  Suk Woo Nam,et al.  PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas , 2005, Oncogene.

[27]  P. Vogt,et al.  Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Horton,et al.  Molecular mediators of hepatic steatosis and liver injury. , 2004, The Journal of clinical investigation.

[29]  T. Mak,et al.  Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. , 2004, The Journal of clinical investigation.

[30]  M. Reitman,et al.  Liver Peroxisome Proliferator-activated Receptor γ Contributes to Hepatic Steatosis, Triglyceride Clearance, and Regulation of Body Fat Mass* , 2003, Journal of Biological Chemistry.

[31]  M. Tai,et al.  Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma , 2003, Cancer.

[32]  Hong Wu,et al.  PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. , 2003, Cancer cell.

[33]  L. Hennighausen,et al.  Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. , 2002, Development.

[34]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[35]  R. Glazer,et al.  Delayed mammary gland involution in MMTV-AKT1 transgenic mice , 2002, Oncogene.

[36]  R. Cardiff,et al.  Activation of Akt (Protein Kinase B) in Mammary Epithelium Provides a Critical Cell Survival Signal Required for Tumor Progression , 2001, Molecular and Cellular Biology.

[37]  C Eng,et al.  PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways. , 2001, Human molecular genetics.

[38]  P. Vogt,et al.  The akt kinase: molecular determinants of oncogenicity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. Wigler,et al.  The lipid phosphatase activity of PTEN is critical for its tumor supressor function. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Kenneth M. Yamada,et al.  Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. , 1998, Science.

[41]  C. Day,et al.  Steatohepatitis: a tale of two "hits"? , 1998, Gastroenterology.

[42]  F. Chisari,et al.  Hepatitis C virus core and E2 protein expression in transgenic mice , 1997, Hepatology.

[43]  J. Deslypere.  Obesity and cancer. , 1995, Metabolism: clinical and experimental.

[44]  R. A. Clark,et al.  Visceral obesity and breast cancer risk , 1994, Cancer.

[45]  S. Nagata,et al.  Lethal effect of the anti-Fas antibody in mice , 1993, Nature.

[46]  R. Palmiter,et al.  An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice. , 1987, Genes & development.

[47]  L. Garfinkel.  Overweight and cancer. , 1985, Annals of internal medicine.

[48]  M. Cohn,et al.  Transformed cell lines susceptible or resistant to in vivo surveillance against tumorigenesis , 1978, Nature.

[49]  M. Vinciguerra,et al.  PTEN down-regulation by unsaturated fatty acids triggers hepatic steatosis via an NF-kappaBp65/mTOR-dependent mechanism. , 2008, Gastroenterology.